Analysts turn bullish on Neopharm's IL-13

Shares of Neopharm have been swelling in recent months as the biotech draws closer to gathering the final data in its late-stage trial of its brain tumor shrinking therapy IL-13 (cintredekin besudotox). An independent committee has recommended that the trial continue until 215 of the 300 volunteers in it die, a figure that could be reached in three months. Following that point, Neopharm will determine when it will file for FDA approval. If it wins approval, Neopharm indicates that it will use its sales force of 40 people to commercialize the therapy at top centers.

- check out the article from The Chicago Tribune on Neopharm

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.